PDCD1 and non-small cell lung carcinoma: Given that the predictive value of biomarkers can vary depending on cancer types and stages, as exemplified by PD‐1 expression levels mentioned previously, investigating microbial profiles and underlying mechanisms in early‐stage NSCLC treated with neoadjuvant immunochemotherapy could yield significant clinical implications.